Kymera Therapeutics Inc Cash Flow-to-Debt Ratio
Kymera Therapeutics Inc cash flow-to-debt ratio. Kymera Therapeutics Inc (KYMR) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of $-54.06 Million could theoretically repay 0% of its total liabilities ($139.85 Million) in one year. See KYMR financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kymera Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Kymera Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Kymera Therapeutics Inc across 8 annual periods. Check Kymera Therapeutics Inc (KYMR) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kymera Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Kymera Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Kymera Therapeutics Inc. For the full cash flow conversion analysis, see cash flow conversion of Kymera Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.43x | $-232.89 Million | $163.15 Million | ▼ -4.5% |
| 2024 | -1.37x | $-194.50 Million | $142.42 Million | ▼ -140.1% |
| 2023 | -0.57x | $-102.83 Million | $180.79 Million | ▲ +58.0% |
| 2022 | -1.35x | $-153.09 Million | $112.98 Million | ▼ -53.7% |
| 2021 | -0.88x | $-128.95 Million | $146.27 Million | ▼ -303.4% |
| 2020 | 0.43x | $88.13 Million | $203.29 Million | ▲ +362.7% |
| 2019 | 0.09x | $17.91 Million | $191.11 Million | ▲ +141.3% |
| 2018 | -0.23x | $-17.86 Million | $78.67 Million | — |